Compare Abeona Therapeutics Inc (ABEO) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fastly Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Fastly Inc trades at $19.05 (market cap $2.91B). The key difference: Fastly Inc is far larger — about 7.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FSLY | |
|---|---|---|
Market Cap | $373.32M | $2.91B |
Sector | Health | Technology |
52-Week High | $7.23 | $33.50 |
52-Week Low | $4.17 | $6.36 |
Enterprise Value | $228.22M | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Fastly (FSLY) trades at $18.59, up 2.54% with a bullish technical signal and positive earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows improving revenue growth (20% YoY in Q1 2026) and margin expansion, though it remains unprofitable with a -15.79% net income margin. Recent positive developments include Gartner recognition and strategic AI partnerships, while analyst consensus leans neutral with a $25.80 price target representing 39% upside potential.
Fastly presents a growth opportunity in edge cloud infrastructure with strong AI-driven demand, but carries execution risks amid ongoing losses. The stock's valuation at 4.18x sales appears reasonable for a 20% grower, though competitive pressures and high infrastructure spending require careful monitoring. Current technical strength near key support at $18 suggests near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
